Overcoding is a common term used when discussing fraud and abuse in reporting procedures and services not supported by the actual work performed. Alternatively, undercoding—or failing to report the full extent of services or procedures provided—is an equally unsound practice and a compliance risk. In the world of quality reporting, undercoding can have damaging effects…
There is a saying that if the American Medical Association (AMA) did not exist, we would have to invent it. That is just what Dr. Nathan S. Davis did back in 1845 when he called for a national medical convention and laid the foundation for the establishment of the AMA in 1847. This new group would…
After 39 years in rheumatology practice, Herbert Baraf, MD, says, “Management has a great influence over the quality of practice.” Here are some tips for physician management…
The ACR continues to broaden its advocacy efforts on issues critical to rheumatology, as described in updates to its 2017 health policy statements. Along with continuing to advocate for access to care and treatments, enhancements to rheumatology research and training the next generation of rheumatologists, the 2017 health policy statements address a number of new…
Patient Safety & Site of Service for Biologics Although emphasizing its strong support for the use of biologic agents as necessary treatments for rheumatic diseases, the ACR Board of Directors continues to be concerned about the safe delivery of these agents, given the potential for associated adverse events and infusion reactions. In a position statement…
Rheumatologists are accustomed to educating patients about medications, but biologic medications—and now biosimilars—require some additional time and discussion. “Biologics are inherently more complex [than other medications], and there are multiple issues to consider before initiating treatment,” says K. “Kwas” Huston, MD, The Center for Rheumatic Disease, Kansas City, Mo. The first FDA-approved biosimilar to become…
Rheumatologists are accustomed to educating patients about medications—but biologic medications require some additional time and discussion. “Biologics are inherently more complex [than other medications], and there are multiple issues to consider before initiating treatment,” says K. “Kwas” Huston, MD, The Center for Rheumatic Disease, Kansas City, Mo. “This includes the patient’s disease activity, prior medications…
A new presidential administration took office in January 2017. Although no one truly knows what directions our government and economy will take, one projection is that healthcare regulatory and insurance coverage policies will change, possibly dramatically. In a time of uncertainty, rheumatologists and rheumatology health professionals can turn to the ACR/ARHP for support, guidance and…
(Reuters)—U.S. Sen. Claire McCaskill (D-Mo.) on Thursday asked Kaleo Pharmaceuticals to justify the more than 550% surge in the price of its device to treat opioid overdoses, becoming the second senator to question Evzio’s $4,500 price tag. Evzio contains the overdose-reversing drug naloxone and can be used in emergencies by people without medical training. Privately…
ATLANTA—Despite a downpour outside, ACR and ARHP leaders enjoyed sunny news about the Rheumatology Informatics System for Effectiveness (RISE) Registry at the on Jan. 21. RISE now includes data on more than 4 million patient encounters, and attendees were charged with thinking of ways to increase utilization of the registry and better use its valuable information….